Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Metachromatic Leukodystrophy (MLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline landscape. Metachromatic leukodystrophy is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. Symptoms include vision problems ... Read More
-
Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape. Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, ... Read More
-
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... I) (Hurler Syndrome ) - Drugs In Development, 2022, provides an overview of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) (Genetic Disorders) pipeline landscape. MPS I (Mucopolysaccharidosis I) is an inherited lysosomal storage disorder ... Read More
-
North America Atopic Dermatitis Drugs Market Size, Share & Industry Trends Analysis Report By Route of Administration, By Class (Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors), By Country and Growth Forecast, 2022 - 2028
... America Atopic Dermatitis Drugs Market would witness market growth of 8.6% CAGR during the forecast period (2022-2028). An eczema flare-up can be caused by a wide range of internal and external physical conditions. Increased blood ... Read More
-
Anemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Chronic Kidney Disease (Renal Anemia) - Drugs In Development, 2022, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape. Renal anemia is a disease in which the patient ... Read More
-
Pertussis (Whooping Cough) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Pertussis (Whooping Cough) (Infectious Disease) pipeline landscape. Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms ... Read More
-
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report GMDHC22228TDB, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics, ... Read More
-
Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape. Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease ... Read More
-
Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape. Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in ... Read More
-
Wilson Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Wilson Disease (Genetic Disorders) pipeline landscape. Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, ... Read More
-
Bile Duct Cancer (Cholangiocarcinoma) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
... will be more than 71,000 diagnosed prevalent cases of bile duct cancer across 16 pharmaceutical markets. There are seven marketed innovator drugs for the treatment of bile duct cancer, mostly tyrosine kinase inhibitors. R&D activity ... Read More
-
Sicca Syndrome (Sjogren) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Sicca Syndrome (Sjogren) (Immunology) pipeline landscape. Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or ... Read More
-
Radiodermatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Radiodermatitis (Toxicology) pipeline landscape. Radiodermatitis is an inflammation of the skin caused by radiation. Several factors can be attributed to the varying response of patients' skin to radiation therapy such as treatment-related ... Read More
-
Ornithine-Transcarbamylase Deficiency Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline landscape. Ornithine transcarbamylase (OTC) deficiency is a rare X-linked genetic disorder characterized by complete or partial lack of the enzyme ornithine transcarbamylase (OTC). OTC plays ... Read More
-
Liver Failure (Hepatic Insufficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Drugs In Development, 2022, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape. Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is ... Read More
-
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... II) (Hunter Syndrome ) - Drugs In Development, 2022, provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Genetic Disorders) pipeline landscape. Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, ... Read More
-
Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Melanoma (Oncology) pipeline landscape. Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the ... Read More
-
Europe Atopic Dermatitis Drugs Market Size, Share & Industry Trends Analysis Report By Route of Administration, By Class (Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors), By Country and Growth Forecast, 2022 - 2028
... Dermatitis Drugs Market would witness market growth of 9.0% CAGR during the forecast period (2022-2028). Transepidermal water loss (TEWL) is far more common in atopic dermatitis sufferers than in healthy individuals, and xerotic portions of ... Read More
-
Global Atopic Dermatitis Drugs Market Size, Share & Industry Trends Analysis Report By Route of Administration, By Class (Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors), By Regional Outlook and Forecast, 2022 - 2028
... Dermatitis Drugs Market size is expected to reach $22 billion by 2028, rising at a market growth of 9.2% CAGR during the forecast period. Eczema, commonly referred to as atopic dermatitis, is a skin ailment ... Read More
-
Global Biosimulation Market (2022 Edition) – Analysis By Component (Software, Service), Application (Drug Discovery, Pre-Clinical, Clinical), End-User, By Region, By Country: Market Insights and Forecast (2018-2028)
... Azoth Analytics in November 2022, the Global Biosimulation Market was valued at USD 3011.50 Million in the year 2021. Biosimulation helps to increase the probability of success in human clinical trials, the most expensive part ... Read More
-
Glaucoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
... than 18 million total prevalent cases of glaucoma across 16 pharmaceutical markets. There are 10 marketed leading drugs for the treatment of glaucoma, Prostaglandin analogues are generally used as a first-line treatment. The R&D activity ... Read More
-
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update'; Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target ... Read More
-
Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Hypertension (Cardiovascular) pipeline landscape. Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone ... Read More
-
Retinal Vein Occlusion Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape. Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images ... Read More
-
Small-Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape. Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. ... Read More
Research Assistance
